Skip to main content
S&P 5007,617.26+0.87%DOW51,633.11+0.33%NASDAQ26,342.68+1.40%BTC$76,477.00+1.28%ETH$2,456.13+2.89%GOLD$4,408.80+0.49%OIL$100.46-1.92%
Smart Investors Daily
MB

NASDAQ · MBOT

Microbot Medical Inc.

Healthcare · Medical - Instruments & Supplies

$1.44

Up+$0.03 (+1.74%)

Updated Sep 17, 2026, 1:52 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
108.69M
P/E ratio
-12.46
Dividend yield
0.00%
52-week range
$1.42 – $2.86
Volume
289.59K
Avg. volume
3.35M

Price performance

MBOT price history

1M range · 20 trading sessions · Daily adjusted prices

MBOT closed at $1.44 after 20 trading sessions, down 7.10% for the selected period.

Last close
$1.44
Period change
-7.10%
Period low
$1.44
Period high
$1.55
Daily close
View OHLC price history
MBOT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$1.44$1.48$1.43$1.44289.59K
Sep 15, 2026$1.45$1.47$1.43$1.44345.78K
Sep 14, 2026$1.43$1.495$1.42$1.45406.12K
Sep 11, 2026$1.49$1.49$1.44$1.45446.98K
Sep 10, 2026$1.45$1.475$1.45$1.46203.02K
Sep 9, 2026$1.49$1.50$1.45$1.46293.57K
Sep 8, 2026$1.46$1.515$1.45$1.50560.22K
Sep 4, 2026$1.48$1.48$1.44$1.44406.88K
Sep 3, 2026$1.48$1.489$1.44$1.44385.83K
Sep 2, 2026$1.46$1.52$1.46$1.46539.8K
Sep 1, 2026$1.49$1.50$1.465$1.47328.32K
Aug 31, 2026$1.49$1.50$1.46$1.49404.9K
Aug 28, 2026$1.50$1.51$1.46$1.48467.74K
Aug 27, 2026$1.51$1.54$1.49$1.50400.4K
Aug 26, 2026$1.53$1.53$1.47$1.52563.55K
Aug 25, 2026$1.49$1.53$1.4746$1.50587.56K
Aug 24, 2026$1.50$1.57$1.47$1.481.52M
Aug 21, 2026$1.50$1.53$1.49$1.50334.15K
Aug 20, 2026$1.56$1.5661$1.48$1.49613.68K
Aug 19, 2026$1.50$1.56$1.48$1.55723.62K

Latest MBOT news

The latest Smart Investors Daily articles mentioning MBOT.

Stock researchCompany · Overview

MBOT research

Overview

Company profile and research snapshot.

Company profile

Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.50
Implied upside
—
Analysts
—
MBOT recent ratings
DateFirmRatingTarget
Aug 14, 2026B. Riley SecuritiesBuy—
Jun 3, 2026LUCID CAPITAL MARKETSBuy—
Apr 14, 2026HC Wainwright & Co.Buy—
Feb 10, 2026B. Riley SecuritiesBuy—
Dec 3, 2025Roth CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Mar 4, 2026

Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare ProvidersHINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association’s (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for he

Yahoo · Mar 3, 2026

Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event

HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner re

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By